What is Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD)?

Category: Others

false

The MUK five trial is a randomized study of cyclophosphamide and dexamethasone in comparison to bortezomib (Velcade®) with cyclophosphamide and dexamethasone.

Last updated:
There are no evaluations for Myeloma Phase II MUK five (carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, Velcade and dexamethasone (CVD).